ImpediMed
Australian med‑tech firm delivering FDA‑cleared BIS diagnostics for fluid‑status monitoring across oncology, cardiology and metabolic care.
Private Company
Funding information not available
AI Company Overview
Australian med‑tech firm delivering FDA‑cleared BIS diagnostics for fluid‑status monitoring across oncology, cardiology and metabolic care.
Technology Platform
Bioimpedance Spectroscopy (BIS) measuring 256 frequencies in a rapid scan to separate intra‑ and extracellular fluid, integrated into the cloud‑connected SOZO digital health platform for real‑time clinical decision support.
Opportunities
Risk Factors
Competitive Landscape
Competes with other BIS vendors (e.g., ImpediV, LymphAssist) and emerging wearable fluid‑sensing devices; differentiation lies in FDA clearance, multi‑frequency analysis, and a fully integrated cloud platform.